| Catalog No. | HW497016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Isotype | Fusion - [FAS (Fas cell surface death receptor, TNFRSF6, tumor necrosis factor receptor (TNFR) superfamily member 6, FAS1, APO-1, CD95)]2 - IGHG1 Fc (Fragment constant) |
|---|
| Expression system | Mammalian Cells |
|---|
| Target | Receptor-binding FasL ectodomain, APL, APT1LG1, FasL ICD, Fas antigen ligand, CD178, sFasL, CD95L, APTL, TNFSF6, Apoptosis antigen ligand, SPA, FASLG, FasL, SPPL2A-processed FasL form, Tumor necrosis factor ligand superfamily member 6, Soluble Fas ligand, Fas ligand, CD95 ligand, CD95-L, FASL |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P48023 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -1196°C. |
|---|
| Alternate Names | APG-101,CAS:1450882-18-4 |
|---|
| Background | Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD). |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
